(Q37732234)

22 August 2017

1 reference

title

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor (English)

1 reference

chronic obstructive pulmonary disease

22 August 2017

0 references

author name string

Nicholas J Gross

series ordinal

1

1 reference

22 August 2017

Mark A Giembycz

series ordinal

2

1 reference

22 August 2017

Stephen I Rennard

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

2

1 reference

22 August 2017

141-153

1 reference

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Treatment of stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

What have we learned from large drug treatment trials in COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Chronic obstructive pulmonary disease: current burden and future projections.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

COPD: current therapeutic interventions and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Mechanisms in COPD: differences from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

PDE4 inhibitors - a review of the current field

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Single-dose pharmacokinetics of roflumilast in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Influence of Cigarette Smoking on Drug Metabolism in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412551003758304

10.3109/15412551003758304

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference